High-performance lead-free K0.5Na0.5NbO3 piezoelectric ceramics present a practical alternative to lead-containing counterparts by effectively reducing potential environmental hazards. This advancement is particularly relevant to the development of ferroelectric heterojunction devices for biomedical applications. Here, we design and fabricate a frequency-adjustable ferroelectric heterojunction based on the developed K0.5Na0.5NbO3 piezoelectric ceramics with a high piezoelectric coefficient (d33 = 680 pC/N). By leveraging flexible encapsulation, the heterojunction achieves miniaturization (φ = 13.3 mm, h = 2.28 mm) and suitability for implantation. After penetrating the rat skull, the ultrasound generated by the heterojunction at a frequency of 3 MHz reaches a focal depth of about 7.9 mm, a focal width of approximately 480 μm at −6 dB, and millimeter-scale continuous focal tuning (1.5 mm) within a narrow frequency range (2.7–3.3 MHz). Additionally, the implanted heterojunction enables long-term and high-precision transcranial neuromodulation, and consequently yields therapeutic effects in a myocardial infarction animal model. Collectively, this study highlights a viable strategy for developing and applying lead-free ferroelectric heterojunctions, expanding their potential in brain modulation, and providing new insights into clinical treatments of myocardial infarction.
Background - Proton beam therapy offers radiophysical properties that are appealing for noninvasive arrhythmia elimination. This study was conducted to use scanned proton beams for ablation of cardiac tissue, investigate electrophysiologic outcomes, and characterize the process of lesion formation in a porcine model using particle therapy. Methods - Twenty-five animals received scanned proton beam irradiation. ECG-gated CT scans were acquired at end-expiration breath hold. Structures (atrioventricular junction [AVJ] or left ventricular myocardium [LV]) and organs at risk were contoured. Doses of 30, 40, and 55Gy were delivered during expiration to the AVJ (AVJ; n=5) and LV myocardium (LV; n=20) of intact animals. Results - In this study, procedural success was tracked by pacemaker interrogation in the AVJ group, time-course magnetic resonance imaging (MR) in the LV group, and correlation of lesion outcomes displayed in gross and microscopic pathology. Protein extraction (active caspase-3) was performed to investigate tissue apoptosis. Doses of 40 and 55Gy caused slowing and interruption of cardiac impulse propagation at the AVJ. In 40 LV irradiated targets, all lesions were identified on MR after twelve weeks, being consistent with outcomes from gross pathology. In the majority of cases, lesion size plateaued between 12 and 16 weeks. Active caspase-3 was seen in lesions 12 and 16 weeks after irradiation, but not after 20 weeks. Conclusions - Scanned proton beams can be used as a tool for catheter-free ablation, and time-course of tissue apoptosis was consistent with lesion maturation.
Sympathetic overactivation and inflammation are two major mediators to post-myocardial ischemia-reperfusion (I/R)-induced ventricular arrhythmia (VA). The vicious cycle between microglia and sympathetic activation plays an important role in sympathetic hyperactivity related to cardiovascular diseases. Recently, studies have shown that microglial activation might be attenuated by light-emitting diode (LED) therapy. Therefore, we hypothesized that LED therapy might protect against myocardial I/R-induced VAs by attenuating microglial and sympathetic activation. Thirty-six male anesthetized rats were randomized into four groups: control group (n = 6), LED group (n = 6), I/R group (n = 12), and LED+I/R group (n = 12). I/R was generated by left anterior descending artery occlusion for 30 min followed by 3 h reperfusion. ECG and left stellate ganglion (LSG) neural activity were recorded continuously. After 3 h reperfusion, a programmed stimulation protocol was conducted to test the inducibility of VA. Furthermore, we extracted the brain tissue to examine the microglial activation, and the peri-ischemic myocardium to examine the expression of NGF and inflammatory cytokines (IL-1β, IL-18, IL-6, and TNF-α). As compared to the I/R group, LED illumination significantly inhibited the LSG neural activity (P < 0.01) and reduced the inducibility of VAs (arrhythmia score 4.417 ± 0.358 vs. 3 ± 0.3257, P < 0.01) in the LED+I/R group. Furthermore, LED significantly attenuated microglial activation and downregulated the expression of inflammatory cytokines and NGF in the peri-infarct myocardium. LED therapy may protect against myocardial I/R-induced VAs by central and peripheral neuro-immune regulation.